{
  "title": "Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.",
  "pmid": "40768895",
  "doi": null,
  "affiliations": [
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Division of Immunology, Allergy & Retrovirology, William T. Shearer Center for Human Immunobiology, Baylor College of Medicine, Texas Children's Hospital, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Biostatistics and Data Science, UT Health Houston, Houston, USA.",
    "Oncimmune Germany GmbH, Dortmund, Germany.",
    "Oncimmune Germany GmbH, Dortmund, Germany.",
    "Oncimmune Germany GmbH, Dortmund, Germany.",
    "Oncimmune Germany GmbH, Dortmund, Germany.",
    "Oncimmune Germany GmbH, Dortmund, Germany.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Endeavor Health, Chicago, USA.",
    "Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.",
    "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: anaing@mdanderson.org."
  ]
}